Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
41
Participants
Timeline
Start Date
June 1, 2025
Primary Completion Date
June 1, 2026
Study Completion Date
December 31, 2026
Conditions
Extensive-stage Small Cell Lung Cancer (ES-SCLC)Cancer - Associated Anorexia - Cachexia Syndrome
Interventions
DRUG
Nanocrystalline megestrol acetate
Nanocrystalline megestrol acetate
All Listed Sponsors
lead
Guangzhou Institute of Respiratory Disease
OTHER
NCT06909383 - Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study | Biotech Hunter | Biotech Hunter